Apalutamide Pharma Grade API is supplied under the product codes APL-APA-01, APL-APA-02, and APL-APA-03. These materials are controlled for use in tablets, capsules, granules, oral suspensions, and injectable development. The active substance is a nonsteroidal androgen receptor inhibitor with the molecular formula C₂₁H₁₅F₄N₅O₂S, molecular weight 477.43 g/mol, and CAS Registry Number 956104-40-8. It appears as a white to off-white crystalline powder. The compound is practically insoluble in aqueous media across physiological pH, which makes particle-size reduction and wetting/dispersion strategy the main formulation variables for oral solid and injectable dosage forms. The approved oral tablet strength is 60 mg; capsule, granule, and injectable presentations are not described in approved labeling and must be qualified independently under current good manufacturing practice, including FDA 21 CFR 211.84 for component testing and FDA 21 CFR 211.160 for laboratory controls.

Product code APL-APA-01 is the air-jet-milled oral solid grade. Particle-size distribution is controlled by laser diffraction using ISO 13320:2020 with D90 ≤25 µm and D50 3–10 µm. APL-APA-02 is the unmicronized oral granulation grade; it has a larger D90 ≤75 µm and is selected when particle size reduction will be performed during wet granulation or roller compaction. APL-APA-03 is the injectable-development grade with bacterial endotoxin controlled to <0.5 EU/mg by Ph. Eur. 2.6.14 and bioburden controlled to ≤100 CFU/g. APL-APA-03 is not sterile; the finished injectable product must be sterilised by a validated process or processed aseptically after formulation.

What release specification governs apalutamide API supplied for tableting and injectable development?

Release controls are based on the impurity threshold framework of ICH Q3A(R2), residual solvent limits of ICH Q3C(R8), and elemental impurity limits of ICH Q3D(R2). Assay by HPLC with ultraviolet detection is controlled at 98.0–102.0% on the anhydrous and solvent-free basis. Total related substances are limited to ≤1.0%; any unspecified individual impurity is limited to ≤0.10%. Residual solvent limits include methanol ≤3000 ppm, N,N-dimethylformamide ≤880 ppm, tetrahydrofuran ≤720 ppm, and ethanol ≤5000 ppm. Elemental impurities by inductively coupled plasma mass spectrometry follow ICH Q3D Option 1, with palladium ≤10 µg/g, nickel ≤20 µg/g, and arsenic ≤15 µg/g. Water content by Karl Fischer titration is ≤0.5%. Crystalline identity is confirmed by X-ray powder diffractometry against a controlled reference diffractogram. Method validation for assay and related substances follows ICH Q2(R1); system suitability includes resolution between apalutamide and its closest specified impurity.

Solid-state analysis is performed by X-ray powder diffractometry and differential scanning calorimetry. The melting endotherm is controlled against a reference crystalline form; solvated or recrystallised variations are considered out of specification because they alter dissolution and processing behaviour. Surface area is reported for the micronized grade because it correlates with dissolution rate in the low-solubility formulation environment. Bulk density and tapped density are also reported, as both parameters influence die fill and capsule fill weight. The specification described here is a release specification, not a guarantee of performance in every finished formulation. The API manufacturer provides batch-specific certificates of analysis and a technical dossier containing method validation summaries, forced degradation data, and residual solvent and elemental impurity profiles. The batch-to-batch variability of the micronized grade is controlled through process validation and annual product quality review under ICH Q7.

At production scale, the unmicronized APL-APA-02 powder is cohesive and does not flow reliably through gravity-fed rotary tablet press hoppers. Direct compression without a granulation step has produced weight variation exceeding USP <905> acceptance criteria when tableting speed exceeds approximately 40 rpm on a 10-station rotary press equipped with standard B-tooling; published production-scale data for this specific configuration is limited. Pre-blending with microcrystalline cellulose and colloidal silicon dioxide improves flow but does not remove the need for forced feed frames or vacuum-assisted die filling. Pre-drying at 40 ±5 °C for 4 h is recommended when ambient relative humidity exceeds 60% because the powder becomes cohesive and may adhere to punch faces and capsule dosator surfaces. Apalutamide should not be blended with strong oxidising agents or with acidic excipients that promote hydrolytic degradation unless forced degradation studies support compatibility.

When direct compression is not feasible, roller compaction and wet granulation routes diverge

When direct compression is not feasible, the tablet formulation route shifts to either dry roller compaction or high-shear wet granulation. Wet granulation in a high-shear granulator typically uses povidone K30 at 2–5% w/w binder solids and either water or an ethanol-water mixture. The endpoint is controlled by impeller torque or current; wet mass is passed through a 1.0–1.5 mm screen and dried at 50–60 °C until loss on drying is ≤2.0%. The dried granules are milled and blended with disintegrant and lubricant. For immediate-release tablets, dissolution is evaluated with USP <711> apparatus II at 75 rpm in pH 1.2, 4.5, and 6.8 media; the low aqueous solubility of apalutamide means that the dissolution profile is highly sensitive to particle size and granule porosity. For capsules, the dried granules are filled on a dosator or tamping-pin encapsulation machine; fill weight uniformity is assessed by USP <905> or current pharmacopoeial equivalent. Roller compaction is preferred when hydrolytic degradation must be minimised. Ribbons are compressed to a target density that produces a milled granule D50 below 500 µm; fines below 75 µm are limited to ≤35% because increased fines reduce flow and can produce capping or weight variation.

Granule products for sachet or suspension require additional wetting and suspending agents because apalutamide is practically insoluble. Aqueous suspensions are developed with polysorbate- or poloxamer-based wetting agents and viscosity-building polymers; homogenisation at high shear reduces the mean particle size and improves dissolution. The granule blend is dried to moisture ≤2.0% and packaged with desiccant if moisture-sensitive excipients are present. Flow and bulk density are controlled before filling because low-density granules can produce unacceptable fill variation in volumetric sachet fillers. Tablet hardness and friability are tested by crushing strength method in Ph. Eur. 2.9.8 and friability method in Ph. Eur. 2.9.7; finished oral solid products are assessed for dissolution, assay, and impurities according to current pharmacopoeial requirements.

For oral suspension or powder for suspension, the API is first dispersed in a vehicle containing a wetting agent such as polysorbate 80 or poloxamer 188. A viscosity-building polymer such as hypromellose or xanthan gum is added to retard sedimentation. The pH of the vehicle should be selected after solubility-screening in media from pH 2.0 to 7.5; elevated pH may reduce solubility further and should be avoided unless a solubilising carrier is present. Chemical stability studies for solution or suspension dosage forms should follow ICH Q1A(R2). Taste-masking agents are required for oral suspension because apalutamide can produce a bitter taste in aqueous dispersion.

Injectables based on apalutamide require a different control strategy because the API is practically insoluble in aqueous media and sterile filtration of a simple solution is not feasible. APL-APA-03 is supplied with reduced bioburden and endotoxin, but the formulated product must be processed aseptically from this point. A nanosuspension produced by high-pressure homogenisation can be considered for parenteral use; the API particle size should be reduced to D50 below 500 nm and sterility assured by aseptic processing because terminal steam sterilisation data for apalutamide is limited. Alternatively, a lipid or surfactant-based carrier can be used, but the finished product must be assessed for hemolysis, injection-site tolerance, and sterility per Ph. Eur. 5.1.1 and current pharmacopoeial injectable tests. The API is not intended for direct injection as a powder.

Comparative receptor binding does not translate linearly to central nervous system penetration

Apalutamide differs from enzalutamide and bicalutamide in receptor pharmacology, central nervous system distribution, and clinical dose. Apalutamide is a second-generation nonsteroidal androgen receptor inhibitor that binds the ligand-binding domain and inhibits androgen receptor nuclear translocation, DNA binding, and androgen-mediated transcription. Unlike bicalutamide, apalutamide does not show partial agonist activity in non-clinical models. Published receptor-binding studies show that apalutamide and enzalutamide both bind the wild-type androgen receptor with high affinity, but apalutamide has a lower brain-to-plasma exposure than enzalutamide in rodent distribution studies. That difference is relevant to the seizure signal observed in the clinical development programmes. The approved oral dose of apalutamide is 240 mg once daily; enzalutamide is 160 mg once daily; bicalutamide is 50 mg once daily.

For formulation development, the relevant differences between apalutamide and enzalutamide are not limited to receptor binding. Apalutamide has a lower aqueous solubility and a larger clinical dose, which means a 240 mg daily dose may require more than one dosage unit or a higher drug-load tablet. Enzalutamide is formulated as 40 mg soft gelatin capsules or tablets; apalutamide is formulated as 60 mg tablets. The difference in dose and poor solubility makes apalutamide more dependent on particle-size reduction and dispersion than bicalutamide, which is typically used at 50 mg once daily. Direct substitution of one API into the other’s formulation is not appropriate without stability, dissolution, and excipient compatibility studies.